scholarly journals Complementary Use of Label-Free Real-Time Biosensors in Drug Discovery of Monoclonal Antibodies

Biosensors ◽  
10.5772/7204 ◽  
2010 ◽  
Author(s):  
Yasmina Noubia



2011 ◽  
Vol 16 (6) ◽  
pp. 575-587 ◽  
Author(s):  
Franck A. Atienzar ◽  
Karen Tilmant ◽  
Helga H. Gerets ◽  
Gaelle Toussaint ◽  
Sebastien Speeckaert ◽  
...  

The use of impedance-based label-free technology applied to drug discovery is nowadays receiving more and more attention. Indeed, such a simple and noninvasive assay that interferes minimally with cell morphology and function allows one to perform kinetic measurements and to obtain information on proliferation, migration, cytotoxicity, and receptor-mediated signaling. The objective of the study was to further assess the usefulness of a real-time cell analyzer (RTCA) platform based on impedance in the context of quality control and data reproducibility. The data indicate that this technology is useful to determine the best coating and cellular density conditions for different adherent cellular models including hepatocytes, cardiomyocytes, fibroblasts, and hybrid neuroblastoma/neuronal cells. Based on 31 independent experiments, the reproducibility of cell index data generated from HepG2 cells exposed to DMSO and to Triton X-100 was satisfactory, with a coefficient of variation close to 10%. Cell index data were also well reproduced when cardiomyocytes and fibroblasts were exposed to 21 compounds three times (correlation >0.91, p < 0.0001). The data also show that a cell index decrease is not always associated with cytotoxicity effects and that there are some confounding factors that can affect the analysis. Finally, another drawback is that the correlation analysis between cellular impedance measurements and classical toxicity endpoints has been performed on a limited number of compounds. Overall, despite some limitations, the RTCA technology appears to be a powerful and reliable tool in drug discovery because of the reasonable throughput, rapid and efficient performance, technical optimization, and cell quality control.



2021 ◽  
pp. 113469
Author(s):  
Kristof Kliment ◽  
Inna Szekacs ◽  
Beatrix Peter ◽  
Anna Erdei ◽  
Istvan Kurucz ◽  
...  


ChemBioChem ◽  
2021 ◽  
Author(s):  
Spencer A. Shorkey ◽  
Jiale Du ◽  
Ryan Pham ◽  
Eric R. Strieter ◽  
Min Chen
Keyword(s):  


2021 ◽  
Vol 22 (9) ◽  
pp. 4417
Author(s):  
Lester J Lambert ◽  
Stefan Grotegut ◽  
Maria Celeridad ◽  
Palak Gosalia ◽  
Laurent JS De Backer ◽  
...  

Many human diseases are the result of abnormal expression or activation of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Not surprisingly, more than 30 tyrosine kinase inhibitors (TKIs) are currently in clinical use and provide unique treatment options for many patients. PTPs on the other hand have long been regarded as “undruggable” and only recently have gained increased attention in drug discovery. Striatal-enriched tyrosine phosphatase (STEP) is a neuron-specific PTP that is overactive in Alzheimer’s disease (AD) and other neurodegenerative and neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, and fragile X syndrome. An emergent model suggests that the increase in STEP activity interferes with synaptic function and contributes to the characteristic cognitive and behavioral deficits present in these diseases. Prior efforts to generate STEP inhibitors with properties that warrant clinical development have largely failed. To identify novel STEP inhibitor scaffolds, we developed a biophysical, label-free high-throughput screening (HTS) platform based on the protein thermal shift (PTS) technology. In contrast to conventional HTS using STEP enzymatic assays, we found the PTS platform highly robust and capable of identifying true hits with confirmed STEP inhibitory activity and selectivity. This new platform promises to greatly advance STEP drug discovery and should be applicable to other PTP targets.



2021 ◽  
pp. 247255522110006
Author(s):  
Michael D. Scholle ◽  
Zachary A. Gurard-Levin

Arginase-1, an enzyme that catalyzes the reaction of L-arginine to L-ornithine, is implicated in the tumor immune response and represents an interesting therapeutic target in immuno-oncology. Initiating arginase drug discovery efforts remains a challenge due to a lack of suitable high-throughput assay methodologies. This report describes the combination of self-assembled monolayers and matrix-assisted laser desorption ionization mass spectrometry to enable the first label-free and high-throughput assay for arginase activity. The assay was optimized for kinetically balanced conditions and miniaturized, while achieving a robust assay (Z-factor > 0.8) and a significant assay window [signal-to-background ratio > 20] relative to fluorescent approaches. To validate the assay, the inhibition of the reference compound nor-NOHA (Nω-hydroxy-nor-L-arginine) was evaluated, and the IC50 measured to be in line with reported results (IC50 = 180 nM). The assay was then used to complete a screen of 175,000 compounds, demonstrating the high-throughput capacity of the approach. The label-free format also eliminates opportunities for false-positive results due to interference from library compounds and optical readouts. The assay methodology described here enables new opportunities for drug discovery for arginase and, due to the assay flexibility, can be more broadly applicable for measuring other amino acid–metabolizing enzymes.



2013 ◽  
Vol 176 ◽  
pp. 1176-1182 ◽  
Author(s):  
Yuki Aonuma ◽  
Yasuhiko Kondo ◽  
Ayumi Hirano-Iwata ◽  
Atena Nishikawa ◽  
Yasuo Shinohara ◽  
...  


2005 ◽  
Vol 10 (4) ◽  
pp. 258-269 ◽  
Author(s):  
G LEUNG ◽  
H TANG ◽  
R MCGUINNESS ◽  
E VERDONK ◽  
J MICHELOTTI ◽  
...  


2014 ◽  
Vol 105 (6) ◽  
pp. 063118 ◽  
Author(s):  
Daquan Yang ◽  
Shota Kita ◽  
Feng Liang ◽  
Cheng Wang ◽  
Huiping Tian ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document